Company profile: Formula Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of oncology-focused CAR immunotherapies leveraging an allogeneic source, non-viral transfection, and a differentiated immune effector cell, plus diagnostic tests and research reagents including camelid nanobodies, a canine heartworm/tick-borne disease test, a SARS-CoV-2 antigen test, phosphate assay kits, leukocyte isolation solutions, and SDS-PAGE buffers.
Products and services
- Camelid Nanobodies: Engineers camelid-derived nanobodies targeting T-cells, specifically CD4 and CD8, integrated with viral chimeric antigen receptors for targeted engagement, custom-engineered
- PolymorphPrep: Supplies a sterile, endotoxin-tested solution that isolates polymorphonuclear leukocytes from undiluted human whole blood for downstream analysis, research-grade
- SARS-CoV-2 Antigen Test: Produces a detection assay using engineered affinity proteins to identify SARS-CoV-2 antigens in samples, assay-grade
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Formula Pharmaceuticals
Accent Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology therapeutics developing first-in-class DHX9 inhibitors for cancers including those with BRCA loss and mismatch repair deficiencies; potential best-in-class KIF18A inhibitors for multiple indications including ovarian and triple-negative breast cancer; first-in-class small molecule ADAR1 inhibitors for solid tumors; and XRN1 inhibitors for tumors with higher IFN signaling, as monotherapies and with immuno-oncology therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Accent Therapeutics company profile →
Vortex Biosciences
HQ: United States
Website
- Description: Provider of oncology diagnostics integrating cancer biology, microfluidic engineering, and informatics to isolate and characterize circulating tumor cells (CTCs). Offers the VTX-1 Liquid Biopsy System for label-free isolation of viable CTCs from blood, CTC enrichment using disposable cartridges, CTC analysis and downstream assays, and cell handling in formats compatible with different workflows.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vortex Biosciences company profile →
Totient
HQ: United States
Website
- Description: Provider of AI-driven biotechnology leveraging tertiary lymphoid structures to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics, using machine learning and immunoinformatics to pull critical insights from large, complex datasets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Totient company profile →
Mustang Bio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for B-cell Non-Hodgkin Lymphoma, X-linked severe combined immunodeficiency (XSCID), and glioblastoma. Pipeline includes MB-106 (third-generation fully human antibody); MB-107/MB-207 (safety-modified lentiviral gene therapies for XSCID); MB-101 (IL13Rα2-targeted CAR T); MB-108 (oncolytic herpes simplex virus); and MB-109 (combining CAR T with oHSV to improve efficacy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mustang Bio company profile →
AdnaGen
HQ: Germany
Website
- Description: Provider of molecular genetic diagnostic testing systems for medical and clinical research laboratories, offering AdnaTest kits with reagents for immunomagnetic selection, mRNA isolation, and multiplex RT-PCR for tumor diagnostics, and focusing on genetic pre-disposition.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AdnaGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Formula Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Formula Pharmaceuticals
2.2 - Growth funds investing in similar companies to Formula Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Formula Pharmaceuticals
4.2 - Public trading comparable groups for Formula Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →